Other languages Antibe Therapeutics Inc.

Equities

ATE

CA0370255097

Market Closed - Toronto S.E. Other stock markets 08:30:00 16/04/2024 pm IST			5-day change	1st Jan Change
0.295 ^CAD	0.00%		0.00%	-68.28%

24/04	Antibe Therapeutics Inc. Announces Board Resignations	CI
19/04	Antibe Therapeutics Seeks Extension of Stay of Proceedings	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Antibe Therapeutics Inc. Announces Board Resignations	24/04
Antibe Therapeutics Inc. Announces Board Resignations	09/04
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul	01/04
Antibe Therapeutics Inc. Announces Formation of Executive Committee	01/04
Antibe Reported Q3 2024 Interim Financial and Operating Results	14/02
Antibe Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02
Antibe Extending Early Warrant Exercise Incentive Program	01/02
Antibe Therapeutics Announced Early Warrant Exercise Incentive Program	29/12
Antibe Therapeutics Up 4% After Announcing Amendment To Warrant Extension, Price Changes	13/12
Antibe Therapeutics Reports Q3 2023 Net and Comprehensive Loss of $5 Million	13/11
Antibe Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	13/11
Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul?s New Formulation	09/11
Antibe Completes First Clinical Study of Otenaproxesul?s New Formulation	01/11
Antibe Initiates First Clinical Study of Otenaproxesul?s New Formulation	18/23/18
Antibe Therapeutics Receives Approval to Initiate PK/PD Study of Otenaproxesul	28/23/28
Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul	28/23/28
Antibe Therapeutics Reports Q1 Loss of $5.8 Million	14/23/14
Antibe Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14
Antibe Therapeutics Reports 2023 Year-End Results	29/23/29
Antibe Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	29/23/29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Antibe Therapeutics Inc.

Equities

ATE

CA0370255097

Other languages

Filters